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Abstract
Purpose of review—Multiple red cell variants are known to confer protection from malaria.
Here we review advances in identifying new variants that modulate malaria risk and in defining
molecular mechanisms that mediate malaria protection.
Recent findings—New red cell variants, including an innate variant in the red cell’s major Ca2+
pump and the acquired state of iron deficiency, have been associated with protection from clinical
falciparum malaria. The hemoglobin (Hb) mutants HbC and HbS – known to protect carriers from
severe falciparum malaria – enhance parasite passage to mosquitoes and may promote malaria
transmission. At the molecular level, substantial advances have been made in understanding the
impact of HbS and HbC upon the interactions between host microRNAs and Plasmodium
falciparum protein translation; remodeling of red cell cytoskeletal components and transport of
parasite proteins to the red cell surface; and chronic activation of the human innate immune
system which induces tolerance to blood-stage parasites. Several polymorphisms have now been
associated with protection from clinical vivax malaria or reduced P. vivax density, including
Southeast Asian ovalocytosis and two common forms of glucose-6-phosphate dehydrogenase
deficiency.
Summary—Red cell variants that modulate malaria risk can serve as models to identify clinically
relevant mechanisms of pathogenesis, and thus define parasite and host targets for next-generation
therapies.
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In 1949, J.B.S. Haldane suggested that β-thalassemia trait may protect red cells from
Plasmodium infection and thus humans from clinical malaria (1). This general hypothesis –
that red cell variants modulate susceptibility to malaria – has since been investigated for
hemoglobin (Hb) mutants, enzymopathies, ABO blood groups, and acquired iron deficiency.
Specifically, studies have confirmed that protection from severe falciparum malaria is
conferred in African children by heterozygosity for HbA and HbS (HbAS, sickle-cell trait),
hetero- and homozygosity for HbC (HbAC, HbCC) [reviewed in (2)], hemizygosity for
glucose-6-phosphate dehydrogenase (G6PD) deficiency (3), and lack of blood group
antigens A and B (i.e., type O) (4) (Table (3–18)). HbAS and HbCC seem to provide
substantial protection from severe disease (91% and 73%, respectively) (2), but little or no
protection from parasitemia, suggesting that these traits interfere specifically with the
pathogenic mechanisms governing transitions from parasitization to severe and fatal
infections. From a biological point-of-view, these insights highlight the co-evolution of host
and parasite and serve as a model of balancing selection. From a clinical perspective, these
relationships represent a naturally occurring model of protection from severe, life
threatening malaria, which can be used to isolate the mechanisms of parasite pathogenesis.
By preventing malaria parasites from causing disease, these red cell variants can help us
discover clinically significant mechanisms of pathogenesis and investigating them as targets
for future therapeutics.
Plasmodium species
Plasmodium spp. parasites are vector-borne pathogens that infect the red cells of reptiles,
birds, and primates. Five species of Plasmodium (P. falciparum, P. vivax, P. ovale, P.
malariae, and P. knowlesi) parasitize and cause malaria in humans. P. falciparum and P.
vivax cause most episodes of malaria and are therefore the focus of this review. P.
falciparum is endemic in tropical areas worldwide but is transmitted most intensely in sub-
Saharan Africa, where it kills more than 500,000 children each year (19). P. vivax is
endemic in South and Southeast Asia, South America, and the Western Pacific, and is a
major cause of morbidity in these regions.
All five Plasmodium species are transmitted by female Anopheles spp. mosquitoes during a
blood meal on humans. After injection into the skin, sporozoites migrate to the liver,
develop within hepatocytes for 7–10 days, and emerge as a large population of merozoites
capable of invading red cells. This new blood stage of asexual parasite development
produces the clinical syndrome of malaria, and is marked by repeated cycles of merozoite
invasion of red cells, parasite maturation and multiplication within red cells, and merozoite
egress from red cells. During this process, a small fraction of parasites differentiates into
sexual gametocytes, which are ingested by another female anopheline mosquito. In this
vector, gametocytes undergo sexual recombination and eventually develop into sporozoites,
which migrate to the mosquito’s salivary glands and await inoculation into the next human
host.
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Impact of red cell variants on malaria
Malaria is the clinical syndrome that results from infection with Plasmodium spp. parasites.
The symptoms of malaria are notoriously nonspecific, but fever is a cardinal finding in
nearly all clinically significant infections. Additionally, the clinical outcomes of blood-stage
infections vary widely in severity from mild, uncomplicated malaria to severe, life
threatening malaria, which encompasses the often non-overlapping syndromes of cerebral
malaria, severe anemia, and respiratory distress. An estimated 451 million clinical cases of
falciparum malaria occurred in 2007, largely in sub-Saharan Africa, and nearly 3 billion
people are at annual risk of infection with P. vivax, largely in Central Asia (20, 21). As
noted earlier, the interactions between red cell variants and P. falciparum parasites have
generated longstanding interest, and recent studies have begun to define the mechanisms of
these relationships. Even today, there exist few data on the impact of red cell variants upon
other Plasmodium species and the malaria syndromes they cause.
P. falciparum malaria
Recent studies of P. falciparum in West Africa have underscored the influence of red cell
variants on human malaria cases. In extending an earlier study of the influence of known Hb
mutants on severe falciparum malaria (5), Timmann et al. (22) performed a genome-wide
association study (GWAS) of severe malaria in Ghanaian children to identify novel
polymorphisms that modulate susceptibility to this disease. In this study, four loci achieved
genome-wide significance: known variants at the β-globin and ABO blood group loci, a
locus near the MARVELD3 gene which encodes an endothelial tight-junction protein, and a
locus in the ATP2B4 gene which encodes a Ca2+ pump. Although this Ca2+ pump is
expressed in numerous tissues, it serves as the principal pump in red cells, in which P.
falciparum growth may conceivably be disrupted by alterations in Ca2+ homeostasis. This
finding was replicated by the authors in a separate GWAS study in Gambian children, and
awaits functional exploration as a component of yet another mechanism by which red cell
variants may attenuate the virulence of P. falciparum.
A study of P. falciparum transmission in Burkina Faso elegantly demonstrated that human
β-globin mutations influence the transmissibility of P. falciparum parasites. Gouagna et al.
(23) employed several study designs to test whether HbC and HbS children infected with P.
falciparum transmit parasites more efficiently to anopheline mosquitoes. In cross-sectional
surveys, they noted a higher prevalence and greater density of gametocytes in HbC children,
and using in-vivo and ex-vivo blood feeding experiments they reported that HbC or HbS
(compared with HbAA) red cells were associated with two- to four-fold higher transmission
of parasites to mosquitoes. Therefore, these prevalent β-globin mutations seem to protect
individual carriers from life-threatening disease states, while at the same time promoting
transmission of parasites through mosquito vectors and into human populations. These data
highlight how malaria parasites and humans have co-evolved: while P. falciparum parasites
drive the continued inheritance of HbS and HbC in human generations, these mutations
enhance the continued transmission of these parasites into successive mosquito populations.
In Uganda, Gong et al. (24) conducted a longitudinal study of HbAA and HbAS children to
better characterize the natural history of P. falciparum infections and the patterns of
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protection from asymptomatic parasitemia and symptomatic malaria. In a mesoendemic
setting, 601 children aged 1–10 years were followed frequently over 18 months for parasite
genotypes, patent parasitemia, and malaria episodes. Compared to HbAA children, HbAS
children had a lower “molecular force of infection” (i.e., the number of new parasite strains
in a person per year), suggesting that P. falciparum established fewer blood-stage infections
in HbAS children. Once parasitemic, HbAS children had lower parasite densities and less
likelihood to develop malaria symptoms. These three measures of protection were more
pronounced with increasing age, suggesting that HbAS protects in part through an acquired
mechanism. HbAS children were also less likely to have hyperparasitemia, but protection
from this life-threatening phenotype was greater in younger than in older children,
suggesting it is mediated by an innate mechanism. Identifying specific innate and acquired
immune responses that enhance HbAS-mediate protection may inform vaccine design.
Further investigations should also explore potential roles of the HbAS red cell itself in
augmenting immune responses, for example, by acting as an adjuvant.
Most studies of red cell variants and malaria have investigated innate disorders, but a recent
study by Gwamaka et al. (25) explored the impact of the acquired state of iron deficiency
upon the risk of malaria. In a longitudinal study of Tanzanian children with frequent, active
follow-up visits, iron deficiency at routine, well-child visits reduced the risk of subsequent
parasitemia, severe malaria, and malaria-attributable mortality. Because diagnosing iron
deficiency in such settings is challenging, the authors employed multiple definitions of iron
deficiency using various cut-off values for serum levels of ferritin, C-reactive protein, and
transferrin receptor – all of which were associated with similar risk reductions. These data
suggest that iron deficiency protects children from severe and fatal falciparum malaria,
though it remains unclear if the mechanisms of this effect occur principally in the red cells
or sera of these children.
P. vivax malaria
Southeast Asian ovalocytosis (SAO, conferred by the band 3 deletion SLC4AΔ27) is lethal
in the homozygous state but achieves high prevalences in the heterozygous state in Papua
New Guinea (PNG), suggesting balancing selection conferred by some survival advantage in
this geographic area. SAO has previously been associated with reduced risk of cerebral P.
falciparum malaria in PNG (18), and Rosanas-Urgell and colleagues (26) hypothesized that
it may also confer protection from P. vivax malaria. In three complementary clinical studies
in PNG, SAO was associated with a 43% reduced incidence of vivax malaria in a
prospective cohort of children, and possibly with reduced risk of severe vivax malaria as
well. SAO was not associated with other protective red cell phenotypes, such as low
expression of the Duffy antigen receptor for chemokines (DARC, an invasion receptor for P.
vivax) or the presence of α-thalassemia. Additional field- and laboratory-based studies are
needed to confirm and elucidate the mechanism of this newly discovered protection.
Two recent studies have explored the influence of G6PD deficiency on P. vivax infection.
Louicharoen et al. (27) investigated the G6PD-Mahidol variant, which reduces enzyme
function by 5 to 32% and is prevalent in several ethnic groups in malarious areas of
Southeast Asia. Population genetics analyses indicated significant, recent positive selection
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of G6PD-Mahidol in human populations, suggesting it confers a clinical benefit to carriers.
In partial support of this possibility, clinical studies found an allele-dependent reduction in
P. vivax density in both males and females; however, this variant was not associated with the
frequency of malaria episodes or the prevalence of P. falciparum parasitemia.
In complementary work, Leslie et al. (28) conducted a case-control study of P. vivax malaria
and its relationship with G6PD deficiency on the Afghanistan-Pakistan border. Phenotypic
G6PD deficiency was significantly reduced among the cases of vivax malaria, and genotypic
deficiency (G6PD-Mediterranean) was reduced in both males and females, providing further
evidence that this class II–III variant protects carriers from vivax malaria. Taken together,
these studies establish an evidence base for exploring the impact of red cell variants upon
vivax malaria, and suggest that this disease has historically been severe enough to impair
fitness and to naturally select red cell variants that are potentially deleterious.
Mechanisms of protection against malaria
The mechanisms by which red cell variants confer protection from malaria have not been
definitively elucidated (Fig. 1) [reviewed in (29) and (30)]. While recent studies have
elucidated remarkable cellular, molecular, and immunological impacts of HbS upon red cell
parasitization and malaria risk, further efforts are required to more finely characterize these
phenomena and exploit them in the development of clinical interventions.
Effects on parasite pathogenicity
Two studies have highlighted the dialogue between red cells and P. falciparum and explored
how these interactions are impacted by β-globin mutations. HbCC and HbAS red cells
reduce the expression and impair the function of P. falciparum erythrocyte membrane
protein 1 (PfEMP1) variants (31, 32), which principally mediate the binding of infected red
cells to extracellular host receptors. Using electron tomography of infected HbAA, HbCC,
and HbSC red cells, Cyrklaff et al. (33) investigated the intraerythrocytic machinery that P.
falciparum establishes de novo and utilizes to traffic its PfEMP1 proteins to the red cell
surface. In HbAA red cells, parasites mined their host cell actin and used it to construct an
intracellular network for transporting parasite proteins – including PfEMP1 – to the red cell
surface. In HbCC and HbSC red cells, parasites developed normally but the cytoskeletal
network was aberrant in appearance, and the transport of parasite-derived proteins to the red
cell surface was impaired. Because these parasite-derived surface proteins mediate the
pathogenicity and immunogenicity of infected red cells, these findings suggest new avenues
by which their expression may be modified for clinical benefit.
In another study, LaMonte et al. (34) explored the interactions of human red cell
microRNAs (miRNAs) upon P. falciparum development and how this relationship may be
modified by HbS. The premises of their experiments were that P. falciparum development is
attenuated in HbAS and HbSS red cells under low oxygen tension (35, 36), and that these
cells manifest altered miRNA profiles (37). Remarkably, the investigators demonstrated that
host miRNAs are transported into the parasite, where they can fuse with parasite mRNA to
produce chimeric host-parasite RNAs which demonstrate aberrant translation and function.
Furthermore, transfection of infected HbAA red cells with host miRNAs that are
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overexpressed in HbAS and HbSS red cells impaired parasite development, modulated
parasite metabolic pathways, and increased parasite differentiation into gametocytes. Given
recent developments in the therapeutic targeting of human miRNAs as a treatment for other
infections (38), these novel miRNA activities in the host-parasite relationship may represent
another pathway for attenuating the virulence of P. falciparum.
Effects on antiparasitic immunity
The mechanisms of innate and adaptive immunity to human malaria remain largely obscure.
Because epidemiologic data suggest that enhanced immunity contributes to protection
conferred by hemoglobinopathies (24, 39), red cell variants may offer a model for
identifying clinically protective, antimalarial immune responses and recapitulating them
with new therapeutics and vaccines. Humoral immunity was explored by Tan et al. (40) in a
longitudinal study of antibody responses to P. falciparum antigens in HbAS and HbAC
children in Mali. By interrogating plasma before and after the malaria transmission season
with a printed array of nearly 500 parasite proteins, the authors demonstrated that these β-
globin variants did not enhance the acquisition of seroreactivity to any of the investigated
antigens. Based on these comprehensive data, it seems unlikely that HbAS or HbAC
generally enhance the development of IgG responses to parasite proteins. It remains
possible, however, that these β-globin variants specifically promote the acquisition of IgG
responses to PfEMP1 and other variant surface antigens that were not well represented on
the array.
A recent study using murine models of HbS and experimental cerebral malaria explored the
interactions between HbS, Plasmodium spp., and the innate immune system. Ferreira et al.
(41) infected mice with the P. berghei ANKA strain and demonstrated that, similar to
humans with HbAS, mice with a sickle-cell trait phenotype did not develop cerebral malaria.
These mice expressed higher levels of heme oxygenase-1 (HO-1), and deletion of the hmox1
gene abrogated the protection afforded by the murine sickle-cell trait. Furthermore,
induction of HO-1 attenuated the elaboration of chemokines implicated in the pathogenesis
of cerebral malaria. Heme itself was protective against murine cerebral malaria when present
in small amounts prior to infection, but deleterious when administered in large amounts after
infection. Together, this series of experiments suggests that HbAS, by keeping free heme
levels chronically elevated, constitutively induces the production of HO-1 which mitigates
heme toxicity after Plasmodium infection and suppresses chemokine levels that normally
cause cerebral malaria. By exploring similar or unrelated mechanisms that enable HbAS
children to “tolerate” Plasmodium infection (Fig. 2), we may discover strategies to prevent
the development of severe and fatal malaria syndromes.
CONCLUSION
Recent studies have successfully identified red cell variants that confer protection from
falciparum and vivax malaria, and have used some of these variants as models to explore the
pathogenesis of falciparum malaria. These latter studies have uncovered novel mechanisms
of disease in which: parasite mRNA and host microRNA fuse to constitute chimeric mRNA
with altered translation; P. falciparum parasites mine host red cell actin in order to remodel
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the cytoskeleton and enable trafficking of parasite proteins to the red cell surface; and
chronic activation of HO-1 and alteration of chemokine profiles mitigates murine cerebral
malaria. These findings reflect promising opportunities to develop future preventive and
therapeutic interventions for malaria.
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• Southeast Asian ovalocytosis and the “Mahidol” and “Mediterranean” variants
of G6PD deficiency protect against vivax malaria, reduce P. vivax parasite
density, or both.
• β-globin variants HbS and HbC confer substantial protection from severe
falciparum malaria but enhance the passage of Plasmodium falciparum to
mosquitoes, which may contribute to onward transmission in human
populations.
• Aberrant host microRNA profiles in HbS-containing red cells may impair P.
falciparum development by forming chimeric fusion mRNA with parasite
transcripts and adversely affecting protein translation.
• HbS and HbC interfere with parasite-dependent remodeling of red cell
cytoskeletal actin and transit of parasite proteins to the red cell surface.
• The chronic release of heme from HbS red cells activates heme oxygenase-1
which mediates protection from cerebral malaria in a murine model, suggesting
a role for the innate immune system in the malaria protective effects of sickle-
cell trait in humans.
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Figure 1. Diverse mechanisms by which red cell variants may influence malaria pathogenesis
A. Plasmodium spp. parasites invade, mature, and replicate in red cells, and these events
may be disrupted by a variety of mechanisms including the influence of host microRNAs on
parasite protein translation, as described by LaMonte et al. (34). B. P. falciparum-infected
red cells cause disease by binding to extracellular receptors on the surface of microvascular
endothelial cells, uninfected red cells, and placental syncytiotrophoblasts via the parasite-
derived surface antigen PfEMP1; trafficking of PfEMP1 to the red cell surface is impaired in
HbS- and HbC-containing cells owing to a disruption of the parasite’s remodeling of the
cell’s actin cytoskeleton, as described by Cyrklaff et al. (33). C. Activation of the innate
immune system by infected red cells, parasite DNA, and free heme can alter the balance of
pro- and anti-inflammatory cytokines to influence pathogenesis, as described by Ferreira et
al. (41). These investigators propose that the chronic release of free heme from HbS-
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containing red cells activates heme oxygenase-1, which then mediates tolerance of
Plasmodium parasites in a murine model of cerebral malaria. D. Plasmodium spp. parasites
may be cleared more efficiently by the adaptive immune system when infecting red cell
variants, though Tan et al. (40) report that children with β-globin variants did not acquire
antibodies to P. falciparum proteins more rapidly or efficiently than children with normal β-
globins. Originally published in Taylor SM, Cerami C, Fairhurst RM. Hemoglobinopathies:
Slicing the Gordian knot of Plasmodium falciparum malaria pathogenesis. PLoS Pathogens
2013;9:e1003327. Made available under the Creative Commons Attribution CCBY license.
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Figure 2. Tolerance of Plasmodium falciparum hyperparasitemia
A 2-year-old Malian boy presented with a history of fever and malaise. Thick and thin blood
films stained with Giemsa showed 273,450 parasites per µL of whole blood (A) and 25.7%
parasitemia (B), respectively. At this time, he had a normal temperature (36.9°C) and
moderate anemia (Hb level 7.8 g/dL). The child received artesunate and amodiaquine over 3
days, never developed symptoms or signs of severe malaria, and was later found to carry the
sickle-cell trait. This case was originally published in Blood. Beaudry JT, Fairhurst RM.
Microvascular sequestration of Plasmodium falciparum. Blood. 2011;117:6410. © the
American Society of Hematology.
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Table
Interactions between innate red cell variants and Plasmodium spp. parasites
Disorder Effects References
β-globin variants
  HbS >90% reduction in risk of severe falciparum malaria by HbAS; >30% reduction in
risk of uncomplicated falciparum malaria by HbAS
(5, 6, 7)
  HbC 73–86% reduction in risk of severe falciparum malaria by HbCC (5, 8)
  HbE Possible protection from severe falciparum malaria by HbAE and HbEE (9)
  HbF Reduced P. falciparum growth in red cells with high HbF content; reduced
cytoadherence of infected red cells with high HbF content
(10, 11)
  β-thalassemia Reduced risk of uncomplicated falciparum malaria (12)
α-globin variants
  α+ trait Small reduction in risk of severe falciparum malaria (5)
  α0 trait 38% reduction in risk of severe falciparum malaria (13)
Surface receptor polymorphisms
  ABO blood group 66% reduction in risk of severe falciparum malaria by blood group O (4)
  Duffy antigen receptor for chemokines
(DARC)
Reduced invasion of DARC-negative, FyFy, red cells by P. vivax in vitro (14)
  Complement receptor 1 Reduced risk of severe falciparum malaria with HL allele (15)
Enzymopathies
  G6PD deficiency Reduced risk of severe falciparum malaria in hemizygous males and homozygous
females
(3)
  Pyruvate kinase deficiency Reduced P. falciparum invasion of deficient red cells and enhanced clearance of
infected red cellsin vitro
(16)
Cytoskeletal abnormalities
  Hereditary spherocytosis Reduced P. falciparum growth in vitro (17)
  Hereditary elliptocytosis Reduced P. falciparum growth in vitro (17)
  Southeast Asian ovalocytosis Protection from cerebral malaria due to P. falciparum (18)
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